Precision-Fermented Ingredient Launch: What Takes Longer
Scale-up, regulatory reviews, customer qualification, reformulation cycles and first contracts: where the time goes when a precision-fermented ingredient goes to market.
Key takeaways
- Scale-up takes longer than the lab plan because commercial fermentation capacity is scarce and every change of site or scale restarts some of the customer's checks.
- In the EU, the novel food route averaged about two and a half years just to reach a published EFSA opinion, before the authorisation step even starts.
- In the US, GRAS may stop being a quiet self-affirmation: a 2026 FDA proposal would make notification mandatory.
- Customer qualification and reformulation run on the buyer's product calendar, which nobody on the supplier side controls.
- The first contracts take longest where the buyer carries the most risk: supply security, second sources and spec changes.
Most plans for a precision-fermented ingredient assume that once the molecule works and the dossier is filed, revenue follows soon after. In my experience it rarely runs that way. The science is usually the part that arrives on time. Everything around it moves at the speed of other people's calendars.
I spent 15 years on the commercial side of specialty chemicals at Solvay and Syensqo, and I now work with Geltor, a biotech collagen company, as fractional head of sales. Nothing below is Geltor-specific; the figures come from public sources. There are five places where the time goes, and founders and buyers can each do something about most of them.
1. Scale-up: the capacity you need may not exist yet
A precision-fermented ingredient that performs at pilot scale still has to be made at a volume and cost a buyer can plan around. That step depends on tanks, downstream processing and a partner with a free slot.
Large tanks are rare. When Synonym Bio mapped global fermentation capacity in February 2023, its database held over 150 facilities, and only 9 had bioreactors of 100,000 litres or more. The same report said most users were searching for demo and commercial-scale capacity that did not exist.
Three years on, the money to close that gap is shrinking. The Good Food Institute's 2026 State of the Industry report on fermentation counts $357 million raised by fermentation companies in 2025, down from $632 million in 2024, and says investment in R&D and manufacturing is "not at levels sufficient" for commercial scale-up.
What founders underestimate is the knock-on effect. A new manufacturing partner, a new strain or a new purification step can change the impurity profile, the colour or the odour. For the customer, that can mean a new sample, a new stability test and sometimes a new safety review. Each scale step resets part of the qualification clock you already ran.
The practical fix is to lock the process before you chase big accounts. If a change is coming anyway, tell customers early and say which of their tests it touches.
2. Regulatory: the clock pauses more than it runs
Regulatory timelines look precise on paper. In practice, the published deadline covers the authority's time and leaves out yours.
EU novel food. EFSA has nine months for its risk assessment, but the clock stops whenever it asks the applicant for more data. After the opinion, the Commission has seven months to ask Member States for theirs, and only then does authorisation follow. A 2025 study in npj Science of Food looked at 292 novel food applications filed from 2018 to 2024. On average it took 2.56 years from submission to a published EFSA opinion. Applications drew 2.7 requests for extra data on average, and applicants' answers took up about 47% of the evaluation time.
That last figure is the useful one for founders. Nearly half the evaluation time was the applicant's, which means dossier quality and response speed are things a team can actually change.
US GRAS. For years, many companies launched food ingredients on a self-affirmed GRAS conclusion, with notification to FDA voluntary. In August 2026 the FDA proposed making GRAS notification mandatory. Under the proposal, FDA would respond within 180 days of filing, with up to two 90-day extensions. Comments are open until 9 December 2026, with an 18-month compliance period after a final rule takes effect. It is a proposal, so nothing changes today. But a US launch plan built on self-affirmation now needs a contingency line.
Cosmetics and chemicals. Personal care is often the faster first market, and it still has its own rules. A substance within REACH scope needs registration once a company makes or imports one tonne or more a year, and brands will still want the safety data for their own product files. Check with a regulatory specialist how your molecule is treated before you promise volumes.
Plan for the data requests before they arrive. One named owner for regulatory answers, with a turnaround target in days, keeps each round from drifting. Customers also want to hear which stage you are in, along with the expected end date.
3. Customer qualification: their calendar, not yours
This is the step I see founders misjudge most often. When a buyer says "we love it" in a first meeting, the evaluation has only just started.
On the buyer side, an ingredient has to clear several teams that each have their own queue. R&D tests it in the target format. Quality audits the supplier and the documentation. Regulatory checks claims and market status. Procurement compares cost and supply risk. Marketing decides whether there is a story worth putting on pack. Any one of them can pause the project, and none of them is measured on how quickly your ingredient gets in.
In my experience the longest part is not the lab work. It is the time a customer needs to understand what a precision-fermented material is: where it comes from, what the process looks like, and how it differs from the traditional way of making the same ingredient. Most of those questions end up at purity, and at how much of the actual molecule is in what you sell. That comes on top of the formulation and stability testing every new raw material goes through.
Samples are another hidden cost. Each format a customer tests can need its own sample size, its own documentation and its own follow-up call. A small startup team can lose weeks just keeping three or four evaluations moving at once.
Ask early who signs off, in what order, and what data each function needs. Then have the documentation pack ready before anyone requests it: spec sheet, safety data, regulatory status by market, allergen and origin statements. A missing document can hold up an evaluation as long as a failed test.
4. Reformulation cycles: the launch window is fixed
Even after an ingredient is qualified, a brand rarely reformulates just to add it. New ingredients enter at the next relaunch, range extension or new product. Those dates are set by the brand's own planning cycle and retail calendar, often well in advance.
So a startup can do everything right and still wait, because the slot is next year. Founders who plan revenue from the date of a successful test usually end up well behind their forecast.
Ask about the customer's next launch window in the first or second meeting. In the forecast and the board deck, keep qualified ingredients without a launch slot in their own line, apart from accounts with a confirmed date.
5. First contracts: where risk changes hands
The first commercial contract is where the buyer moves the risk of a new supplier onto paper. Expect the long discussions in four places.
- Supply security. How much can you deliver, from where, and what happens if a batch fails or a partner plant goes down?
- Second source. Many buyers want a backup for anything critical. For a single-source biotech ingredient, that conversation needs a credible answer early.
- Specification and change control. The buyer wants to know you will not change the process without notice, which ties straight back to the scale-up section.
- Volume and price. Startups want commitments. Buyers want flexibility until the product proves itself in market.
Bring answers on supply continuity and change control before the buyer asks. A short, honest risk note on what could go wrong and what you would do about it earns more trust than a polished deck.
What ingredient buyers can do to shorten the path
Buyers lose time here too: a promising ingredient stuck in qualification is a launch they cannot plan.
A few habits on the buying side shorten the path. Name one internal owner for the evaluation. Share the launch window you are aiming for, even roughly, so the supplier can plan capacity. Tell the supplier early which documents your quality and regulatory teams will need. And if the project is paused, say so, because startups make capacity and hiring decisions on the signals buyers send.
Planning a precision-fermented ingredient launch with realistic timelines
Each of these steps is manageable on its own. The damage comes when they stack up one after another on a plan that assumed they would run in parallel and on time.
A realistic plan for a precision-fermented ingredient separates technical, regulatory and commercial milestones and gives each one an owner. It budgets cash runway for the qualification and reformulation gap as well as the regulatory date. And it starts customer work early, so qualification runs alongside the dossier instead of after it.
This is the kind of work I take on at opencream.partners as a fractional CCO or CBO: go-to-market planning, the first key accounts, and the distributor and agent set-up that follows. If you are mapping this out for your own ingredient, I am happy to compare notes.
Frequently asked questions
How long does EU novel food approval take for a precision-fermented ingredient?
Is self-affirmed GRAS still an option in the US?
Why does customer qualification take so long?
Should a precision fermentation startup launch in cosmetics or food first?
What can ingredient buyers do to speed up evaluations?
Launching an ingredient or opening a new market?
Book a 15-minute call and we'll see where I can help.
Book a Call